Figure 4. Functionality of tumor-infiltrating T-cells is altered by loss of IL18R1.

(A, B) Mice were treated with CCl₄ and orthotopic tumor implantation, and TCRβ⁺CD4⁺CD25⁻ cells (A) and TCRβ⁺CD8⁺ cells (B) were sorted from harvested tumors, mRNA extracted and reverse transcribed, and probed for expression of targets. Fold changes are calculated by normalization to the average expression level in wild-type CD4⁺ (A) and CD8⁺ T-cells (B) for the given experiment. Data pooled from two experiments, total n=7 for wild-type and n=6 for IL18R1-deficient mice. (C–H) Tumor-infiltrating TCRβ⁺CD4⁺ and TCRβ⁺CD8⁺ cells in wild-type and IL18R1-deficient mice were stained for: IFNγ and IL-17a (C-E) or T-bet and Eomes (F–H). Single- and double-stained populations were quantified as percentages of TCRβ⁺CD4⁺ and TCRβ⁺CD8⁺ cells. Statistics: (A, B) multiple t-tests, n=6–7 per group pooled over 2 experiments; (C–H) one-way ANOVA with uncorrected Fisher’s LSD test, n=11–13 per group pooled over 3 experiments for (C–E), n=8–9 per group pooled over 2 experiments for (F–H). NS non-significant; *P<0.05; **P<0.01.